Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Axicabtagene Ciloleucel in patients with refractory large B Cell lymphoma

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 06.12.18
Views: 464

Dr Frederick Locke - Moffitt Cancer Centre, Tampa, USA

Dr Frederick Locke speaks to ecancer at ASH 2018 about the use of axicabtagene ciloleucel in patients with refractory large B cell lymphoma.

He explains that refractory large B cell lymphoma patients have very poor prognosis but that the use of axicabtagene ailoleucel kept 39% patients in remission for a median of 27 months.

Dr Locke adds that this 2 year point is very important in large cell lymphoma as it has been seen that patients who reach this point in remission have a good chance of the lymphoma not returning.

Related videos

follow us

ONJ e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation